At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
fenofibrate +1 moredrug
Likely dose
fenofibrate 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans
In Brief
A Phase 4 clinical trial evaluating fenofibrate and Placebo for Hypertension. Completed, enrolled 75 participants across 1 site.
Detailed Summary
The hypothesis is to test to see if the drug fenofibrate will increase important chemicals in the body and specifically in the kidney, help to rid the body of salt by the kidneys, decrease blood pressure and improve insulin sensitivity during high-salt intake in individuals with hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartSep 2009
Primary CompletionJan 2012
TodayJul 2026
First PostedMar 31, 2009
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.3 years ago
Interventions
fenofibratedrug
Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
Placebodrug
Subjects will be randomized to receive placebo or fenofibrate for five days by mouth